Reports on HIV/AIDS Findings from Department of Infectious Diseases Provide New Insights (Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis).

MLA

“Reports on HIV/AIDS Findings from Department of Infectious Diseases Provide New Insights (Effectiveness and Safety of Dolutegravir plus Lamivudine in Treating HIV in China, Including Outcomes of Patients Coinfected with Tuberculosis).” AIDS Weekly, July 2024, p. 64. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178507366&authtype=sso&custid=ns315887.

APA

Reports on HIV/AIDS Findings from Department of Infectious Diseases Provide New Insights (Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis). (2024). AIDS Weekly, 64.

Chicago

“Reports on HIV/AIDS Findings from Department of Infectious Diseases Provide New Insights (Effectiveness and Safety of Dolutegravir plus Lamivudine in Treating HIV in China, Including Outcomes of Patients Coinfected with Tuberculosis).” 2024. AIDS Weekly, July, 64. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=178507366&authtype=sso&custid=ns315887.